{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:52Z","timestamp":1792036912488,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13300-026-01865-5","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:26:27Z","timestamp":1776227187000},"page":"641-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes"],"prefix":"10.1007","volume":"17","author":[{"given":"Theodoros","family":"Panou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"1","key":"1865_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41572-025-00635-0","volume":"11","author":"R Unnikrishnan","year":"2025","unstructured":"Unnikrishnan R, Shaw JE, Chan JCN, et\u00a0al. Prediabetes. Nat Rev Dis Prim. 2025;11(1):49.","journal-title":"Nat Rev Dis Prim"},{"issue":"14","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jama.2023.4063","volume":"329","author":"JB Echouffo-Tcheugui","year":"2023","unstructured":"Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and management of prediabetes: a review. JAMA. 2023;329(14):1206\u201316.","journal-title":"JAMA"},{"issue":"3","key":"1865_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S2213-8587(25)00034-8","volume":"13","author":"The Lancet Diabetes Endocrinology","year":"2025","unstructured":"The Lancet Diabetes Endocrinology. Prediabetes: much more than just a risk factor. Lancet Diabetes Endocrinol. 2025;13(3):165.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1865_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2337\/dc22-2376","volume":"46","author":"MR Rooney","year":"2023","unstructured":"Rooney MR, Fang M, Ogurtsova K, et\u00a0al. Global prevalence of prediabetes. Diabetes Care. 2023;46(7):1388\u201394.","journal-title":"Diabetes Care"},{"issue":"10","key":"1865_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.tem.2025.01.004","volume":"36","author":"L Sandforth","year":"2025","unstructured":"Sandforth L, Kullmann S, Sandforth A, et\u00a0al. Prediabetes remission to reduce the global burden of type 2 diabetes. Trends Endocrinol Metab. 2025;36(10):899\u2013916.","journal-title":"Trends Endocrinol Metab"},{"issue":"Supplement_1","key":"1865_CR6","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S183\u2013215.","journal-title":"Diabetes Care"},{"issue":"11","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et\u00a0al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"9","key":"1865_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41574-025-01154-4","volume":"21","author":"DS Popovic","year":"2025","unstructured":"Popovic DS, Koufakis T, Patoulias D, Maltese G, Papanas N. The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus. Nat Rev Endocrinol. 2025;21(9):521\u20132.","journal-title":"Nat Rev Endocrinol"},{"issue":"Supplement_1","key":"1865_CR9","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.2337\/dc26-S003","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S50\u201360.","journal-title":"Diabetes Care"},{"issue":"7","key":"1865_CR10","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2337\/db14-1751","volume":"64","author":"K F\u00e6rch","year":"2015","unstructured":"F\u00e6rch K, Torekov SS, Vistisen D, et\u00a0al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes. 2015;64(7):2513\u201325. https:\/\/doi.org\/10.2337\/db14-1751.","journal-title":"Diabetes"},{"issue":"7","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.7150\/ijms.4128","volume":"9","author":"F Zhang","year":"2012","unstructured":"Zhang F, Tang X, Cao H, et\u00a0al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci. 2012;9(7):574\u201381. https:\/\/doi.org\/10.7150\/ijms.4128.","journal-title":"Int J Med Sci"},{"issue":"10160","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et\u00a0al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(18)32260-8.","journal-title":"Lancet"},{"issue":"1","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF00571935","volume":"33","author":"T Linn","year":"1996","unstructured":"Linn T, Schneider K, G\u00f6ke B, Federlin K. Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice. Acta Diabetol. 1996;33(1):19\u201324.","journal-title":"Acta Diabetol"},{"issue":"5","key":"1865_CR14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2337\/diabetes.51.5.1443","volume":"51","author":"C Tourrel","year":"2002","unstructured":"Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51(5):1443\u201352.","journal-title":"Diabetes"},{"key":"1865_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-4684-5616-5_4","volume":"246","author":"Y Goto","year":"1988","unstructured":"Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol. 1988;246:29\u201331.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1865_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1507\/endocrj.EJ12-0094","volume":"60","author":"N Guo","year":"2013","unstructured":"Guo N, Sun J, Chen H, Zhang H, Zhang Z, Cai D. Liraglutide prevents diabetes progression in prediabetic OLETF rats. Endocr J. 2013;60(1):15\u201328.","journal-title":"Endocr J"},{"issue":"9","key":"1865_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2023.159363","volume":"1868","author":"MC Castro","year":"2023","unstructured":"Castro MC, Villagarc\u00eda HG, Schinella G, Massa ML, Francini F. Mechanism of preventive effects of exendin-4 and des-fluoro-sitagliptin in a murine model of fructose-induced prediabetes. Biochimica Biophys Acta (BBA). 2023;1868(9):159363.","journal-title":"Biochimica Biophys Acta (BBA)"},{"issue":"10077","key":"1865_CR18","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, et\u00a0al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"11","key":"1865_CR19","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2337\/dc17-0589","volume":"40","author":"F Santilli","year":"2017","unstructured":"Santilli F, Simeone PG, Guagnano MT, et\u00a0al. Effects of liraglutide on weight loss, fat distribution, and \u03b2-cell function in obese subjects with prediabetes or early type 2 diabetes. Diabetes Care. 2017;40(11):1556\u201364.","journal-title":"Diabetes Care"},{"issue":"8","key":"1865_CR20","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/dom.15113","volume":"25","author":"HJ Silver","year":"2023","unstructured":"Silver HJ, Olson D, Mayfield D, et\u00a0al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023;25(8):2340\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1865_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2337\/db23-0356","volume":"73","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi M, Nian H, Mayfield D, et\u00a0al. Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes. Diabetes. 2024;73(1):38\u201350.","journal-title":"Diabetes"},{"issue":"9","key":"1865_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, et\u00a0al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1865_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et\u00a0al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"12","key":"1865_CR24","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1111\/dom.15269","volume":"25","author":"ER Hankosky","year":"2023","unstructured":"Hankosky ER, Wang H, Neff LM, et\u00a0al. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: post hoc analysis of the SURMOUNT-1 Trial. Diabetes Obes Metab. 2023;25(12):3748\u201356.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1865_CR25","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1111\/dom.70143","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Lebrec J, Lee CJ, et\u00a0al. Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: a post hoc analysis from the three-year SURMOUNT-1 trial. Diabetes Obes Metab. 2025;27(12):7385\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1865_CR26","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2337\/dc25-0763","volume":"48","author":"A Mari","year":"2025","unstructured":"Mari A, Stefanski A, van Raalte DH, et\u00a0al. Tirzepatide treatment and associated changes in \u03b2-cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: a post hoc analysis from the SURMOUNT-1 Trial. Diabetes Care. 2025;48(9):1622\u20137.","journal-title":"Diabetes Care"},{"issue":"9","key":"1865_CR27","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462\u201370.","journal-title":"Diabetes Care"},{"issue":"8","key":"1865_CR28","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1111\/dom.16439","volume":"27","author":"L Zhao","year":"2025","unstructured":"Zhao L, Tao F, Cheng Z, et\u00a0al. Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with tirzepatide: post hoc analysis of SURMOUNT-CN Trial. Diabetes Obes Metab. 2025;27(8):4118\u201325.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1865_CR29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, et\u00a0al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"issue":"6","key":"1865_CR30","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1111\/dom.16349","volume":"27","author":"SA Coon","year":"2025","unstructured":"Coon SA, White RT, Pagnozzi D, Cowart K. Real-world impact of Tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes. Diabetes Obes Metab. 2025;27(6):3526\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"1865_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100283","volume":"22","author":"H Zakaria","year":"2024","unstructured":"Zakaria H, Alshehhi S, Caccelli M, et\u00a0al. Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study. Metab Open. 2024;22:100283.","journal-title":"Metab Open"},{"issue":"8","key":"1865_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et\u00a0al. Weight regain and cardiometabolic effects after withdrawal of Semaglutide: the STEP 1 Trial Extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1865_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, et\u00a0al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199\u2013217.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1865_CR34","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/oby.24360","volume":"33","author":"B Sinha","year":"2025","unstructured":"Sinha B, Ghosal S. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a bayesian NMA. Obesity. 2025;33(11):2046\u201354.","journal-title":"Obesity"},{"issue":"6707","key":"1865_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","volume":"385","author":"KS Kim","year":"2024","unstructured":"Kim KS, Park JS, Hwang E, et\u00a0al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science. 2024;385(6707):438\u201346.","journal-title":"Science"},{"issue":"10","key":"1865_CR36","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Scarlata GGM, Boitos I, et\u00a0al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J Obes (Lond). 2025;49(10):1946\u201357.","journal-title":"Int J Obes (Lond)"},{"key":"1865_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1865_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2025.09.017","author":"B Saha","year":"2025","unstructured":"Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP receptor agonists: effects on the gastrointestinal tract and management strategies for primary care physicians. Mayo Clin Proc. 2025. https:\/\/doi.org\/10.1016\/j.mayocp.2025.09.017. (Online ahead of print).","journal-title":"Mayo Clin Proc"},{"key":"1865_CR39","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.2147\/DMSO.S494919","volume":"17","author":"S Gentinetta","year":"2024","unstructured":"Gentinetta S, Sottotetti F, Manuelli M, Cena H. Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist. Diabetes Metab Syndr Obes. 2024;17:4817\u201324.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"1865_CR40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487\u201395.","journal-title":"Diabetes Care"},{"issue":"1","key":"1865_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12902-023-01291-9","volume":"23","author":"D Khalili","year":"2023","unstructured":"Khalili D, Khayamzadeh M, Kohansal K, et\u00a0al. Are HOMA-IR and HOMA-B good predictors for diabetes and pre-diabetes subtypes? BMC Endocr Disord. 2023;23(1):39.","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"1865_CR42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/dom.16159","volume":"27","author":"KJ Mather","year":"2025","unstructured":"Mather KJ, Mari A, Weerakkody G, et\u00a0al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: an exploratory analysis. Diabetes Obes Metab. 2025;27(3):1507\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1865_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, et\u00a0al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation. 2024;149(6):430\u201349.","journal-title":"Circulation"},{"issue":"4","key":"1865_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100868","volume":"3","author":"CR Howell","year":"2024","unstructured":"Howell CR, Zhang L, Mehta T, et\u00a0al. Cardiometabolic disease staging and major adverse cardiovascular event prediction in 2 prospective cohorts. JACC Adv. 2024;3(4):100868.","journal-title":"JACC Adv"},{"issue":"25 Suppl 2","key":"1865_CR45","first-page":"S49","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, et\u00a0al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373.","journal-title":"Circulation"},{"issue":"1","key":"1865_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02237-8","volume":"23","author":"H Grannes","year":"2024","unstructured":"Grannes H, Ueland T, Simeone P, et\u00a0al. Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):146.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1865_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000298","volume":"13","author":"V Hamidi","year":"2024","unstructured":"Hamidi V, Wang H, Pham V, Bermudez Saint Andre K, Taegtmeyer H, Gutierrez AD. Chronic GLP1 therapy reduces postprandial IL6 in obese humans with prediabetes. Cardiovasc Endocrinol Metab. 2024;13(1):e0298.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"10","key":"1865_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","volume":"16","author":"F Magkos","year":"2020","unstructured":"Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):545\u201355.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1865_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s42255-023-00829-4","volume":"5","author":"JW Beals","year":"2023","unstructured":"Beals JW, Kayser BD, Smith GI, et\u00a0al. Dietary weight loss-induced improvements in metabolic function are enhanced by exercise in people with obesity and prediabetes. Nat Metab. 2023;5(7):1221\u201335.","journal-title":"Nat Metab"},{"issue":"5","key":"1865_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2337\/dc18-0836","volume":"42","author":"J Salas-Salvad\u00f3","year":"2019","unstructured":"Salas-Salvad\u00f3 J, D\u00edaz-L\u00f3pez A, Ruiz-Canela M, et\u00a0al. Effect of a lifestyle intervention program with energy-restricted mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. Diabetes Care. 2019;42(5):777\u201388.","journal-title":"Diabetes Care"},{"issue":"6","key":"1865_CR51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et\u00a0al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"11","key":"1865_CR52","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2015","unstructured":"Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1865_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111939","volume":"219","author":"J Rong","year":"2025","unstructured":"Rong J, Ho M, Zhou D, Chau PH. Responses to lifestyle interventions among individuals with distinct pre-diabetes phenotypes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2025;219:111939.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1865_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2025.103184","volume":"19","author":"X Chai","year":"2025","unstructured":"Chai X, Wang Y, Yin X, et\u00a0al. Effects of lifestyle interventions on the prevention of type 2 diabetes and reversion to normoglycemia by prediabetes phenotype: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2025;19(1):103184.","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"1865_CR55","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2337\/dci24-0040","volume":"48","author":"JB Echouffo-Tcheugui","year":"2025","unstructured":"Echouffo-Tcheugui JB, Chakkalakal RJ, Ali MK. Is the current lifestyle modification approach to diabetes prevention in the U.S. a success? Diabetes Care. 2025;48(6):863\u201370.","journal-title":"Diabetes Care"},{"key":"1865_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100228","volume":"17","author":"JL Sievenpiper","year":"2025","unstructured":"Sievenpiper JL, Ard J, Bl\u00fcher M, et\u00a0al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach. Obes Pillars. 2025;17:100228.","journal-title":"Obes Pillars"},{"key":"1865_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100181","volume":"15","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et\u00a0al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obes Pillars. 2025;15:100181.","journal-title":"Obes Pillars"},{"issue":"1","key":"1865_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal RM, Juhl CR, Jensen SBK, et\u00a0al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41.","journal-title":"Cardiovasc Diabetol"},{"key":"1865_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","volume":"69","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK, Blond MB, Sandsdal RM, et\u00a0al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024;69:102475.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1865_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32307-y","volume":"13","author":"SBK Jensen","year":"2022","unstructured":"Jensen SBK, Janus C, Lundgren JR, et\u00a0al. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022;13(1):4770.","journal-title":"Nat Commun"},{"issue":"9833","key":"1865_CR61","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","volume":"379","author":"AG Tab\u00e1k","year":"2012","unstructured":"Tab\u00e1k AG, Herder C, Rathmann W, Brunner EJ, Kivim\u00e4ki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279\u201390.","journal-title":"Lancet"},{"issue":"11","key":"1865_CR62","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrendo.2011.113","volume":"7","author":"N Papanas","year":"2011","unstructured":"Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7(11):682\u201390.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1865_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3693","volume":"39","author":"D Ziegler","year":"2023","unstructured":"Ziegler D, Herder C, Papanas N. Neuropathy in prediabetes. Diabetes Metab Res Rev. 2023;39(8):e3693.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"1865_CR64","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.3350\/cmh.2024.1150","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim D, Loomba R, Ahmed A. Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023. Clin Mol Hepatol. 2025;31(3):e235\u20138.","journal-title":"Clin Mol Hepatol"},{"issue":"21","key":"1865_CR65","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et\u00a0al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"1865_CR66","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et\u00a0al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"10","key":"1865_CR67","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071\u201394.","journal-title":"Drugs"},{"issue":"8","key":"1865_CR68","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S2213-8587(23)00132-8","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang Y, Shen S, et\u00a0al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2023;11(8):567\u201377.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1865_CR69","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/dci20-0030","volume":"43","author":"WH Herman","year":"2020","unstructured":"Herman WH, Ratner RE. Metformin should be used to treat prediabetes in selected individuals. Diabetes Care. 2020;43(9):1988\u201390.","journal-title":"Diabetes Care"},{"issue":"9","key":"1865_CR70","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2337\/dc19-2221","volume":"43","author":"MB Davidson","year":"2020","unstructured":"Davidson MB. Metformin should not be used to treat prediabetes. Diabetes Care. 2020;43(9):1983\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"1865_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-64","volume":"11","author":"AS Kelly","year":"2012","unstructured":"Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide versus metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11(1):64. https:\/\/doi.org\/10.1186\/1475-2840-11-64.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1865_CR72","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","volume":"66","author":"M Tsch\u00f6p","year":"2023","unstructured":"Tsch\u00f6p M, Nogueiras R, Ahr\u00e9n B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66(10):1796\u2013808.","journal-title":"Diabetologia"},{"issue":"5","key":"1865_CR73","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland ML, Laker RC, Mather K, et\u00a0al. Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2(5):413\u201331.","journal-title":"Nat Metab"},{"issue":"22","key":"1865_CR74","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, et\u00a0al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392(22):2215\u201325.","journal-title":"N Engl J Med"},{"issue":"10401","key":"1865_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, et\u00a0al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529\u201344.","journal-title":"Lancet"},{"issue":"6","key":"1865_CR76","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et\u00a0al. Triple-hormone-receptor agonist retatrutide for obesity\u2014A phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"1865_CR77","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2964","volume":"8","author":"S Tsipas","year":"2025","unstructured":"Tsipas S, Khan T, Loustalot F, Myftari K, Wozniak G. Spending on glucagon-like peptide-1 receptor agonists among US adults. JAMA Netw Open. 2025;8(4):e252964.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1865_CR78","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.7326\/M21-2941","volume":"175","author":"JG Choi","year":"2022","unstructured":"Choi JG, Winn AN, Skandari MR, et\u00a0al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175(10):1392\u2013400.","journal-title":"Ann Intern Med"},{"key":"1865_CR79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp251566","author":"S Gondi","year":"2025","unstructured":"Gondi S, Kesselheim AS, Rome BN. Generic liraglutide\u2014Overlooked but not forgotten. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMp251566. (Online ahead of print).","journal-title":"N Engl J Med"},{"issue":"1","key":"1865_CR80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner R, Heni M, Tab\u00e1k AG, et\u00a0al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49\u201357.","journal-title":"Nat Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01865-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01865-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01865-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:27:25Z","timestamp":1778581645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01865-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01865-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Theodoros Panou has nothing to disclose. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer-Ingelheim, Sanofi and Menarini. Djordje S. Popovic declares associations with: Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and W\u00f6rwag Pharma. Dimitrios Papazoglou declares associations: with Menarini, Novo Nordisk, Astra-Zeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of Astra-Zeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Roche, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, ELPEN, Galenica, KRKA, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda, Viatris and Vianex; and attended conferences sponsored by TrigoCare International, Bayer, Eli-Lilly, Galenica, Novo Nordisk, Pfizer, Viatris and Sanofi-Aventis. Nikolaos Papanas is an Editorial Board member of Diabetes Therapy. Nikolaos Papanas was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}